| Predicate |
Object |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P15-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07B53-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07B61-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C303-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C311-39
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P13-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P13-08 |
| filingDate |
2003-04-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2005-08-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2005523936-A |
| titleOfInvention |
Tamsulosin derivative |
| abstract |
R (−)-5- [2-[[2- is a metabolite of the α 1 -adrenergic effect blocker tamsulosin, which is an optically active compound and has good chemical and optical purity. (2-Ethoxyphenoxy) ethyl] amino] propyl] -2-hydroxybenzenesulfonamide and method for its preparation. A pharmaceutical composition comprising the optically active compound and a therapeutic method comprising administering an effective α 1 -adrenergic antagonistic amount of this composition directly to a mammal. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-4540060-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2007015975-A |
| priorityDate |
2002-04-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |